scholarly journals Viral Suppression Following Switch to Second-line Antiretroviral Therapy: Associations With Nucleoside Reverse Transcriptase Inhibitor Resistance and Subtherapeutic Drug Concentrations Prior to Switch

2013 ◽  
Vol 209 (5) ◽  
pp. 711-720 ◽  
Author(s):  
Victoria Johnston ◽  
Karen Cohen ◽  
Lubbe Wiesner ◽  
Lynn Morris ◽  
Johanna Ledwaba ◽  
...  
Keyword(s):  
Antiretroviral Therapy ◽  
Reverse Transcriptase ◽  
Nucleoside Reverse Transcriptase Inhibitor ◽  
Viral Suppression ◽  
Transcriptase Inhibitor ◽  
Second Line ◽  
Drug Concentrations ◽  
Inhibitor Resistance ◽  
Reverse Transcriptase Inhibitor ◽  
Second Line Antiretroviral Therapy

scholarly journals Differentiated Care Pathways for Antiretroviral Therapy Monitoring in Malawi: Expanding Viral Load Testing in Setting of Highly Prevalent Resistance

2017 ◽  
Vol 4 (3) ◽  
Author(s):  
Sarah E Rutstein ◽  
Kara Compliment ◽  
Julie A E Nelson ◽  
Deborah Kamwendo ◽  
Ronald Mataya ◽  
...  
Keyword(s):  
Antiretroviral Therapy ◽  
Reverse Transcriptase ◽  
Nucleoside Reverse Transcriptase Inhibitor ◽  
Therapy Monitoring ◽  
Transcriptase Inhibitor ◽  
Load Testing ◽  
First Line ◽  
Inhibitor Resistance ◽  
Reverse Transcriptase Inhibitor ◽  
Differentiated Care

Abstract We quantified resistance to first-line antiretroviral therapy among previously unmonitored patients in Malawi with viremia (≥1000 copies/mL). Ninety-five percent (n = 57/61) harbored nucleoside/tide reverse transcriptase inhibitor/non-nucleoside reverse transcriptase inhibitor resistance; resistance was more common comparing >2 (97%) versus ≤2 years (87%) on therapy. Immediate switch for persons retained in care may improve monitoring efficiency and maximize clinical outcomes.

scholarly journals Maintenance of Viral Suppression after Optimization Therapy from Etravirine Plus Raltegravir to Rilpivirine Plus Dolutegravir in HIV-1-Infected Patients

2019 ◽  
Vol 18 ◽  
pp. 232595821882165 ◽  
Author(s):  
Niccolò Riccardi ◽  
Filippo Del Puente ◽  
Lucia Taramasso ◽  
Antonio Di Biagio
Keyword(s):  
Reverse Transcriptase ◽  
Nucleoside Reverse Transcriptase Inhibitor ◽  
Viral Suppression ◽  
Real Life ◽  
Transcriptase Inhibitor ◽  
Strand Transfer ◽  
Immunodeficiency Virus ◽  
Transfer Inhibitor ◽  
Reverse Transcriptase Inhibitor ◽  
Integrase Strand Transfer Inhibitor

Non-nucleoside reverse-transcriptase inhibitor plus integrase strand transfer inhibitor–based dual therapies are an attractive simplification, nucleoside reverse transcriptase inhibitor-sparing strategy for experienced human immunodeficiency virus-infected patients. Thus, we performed a 24-week real-life observational study to assess efficacy and safety of switching from raltegravir plus etravirine to dolutegravir plus rilpivirine in 7 previously heavily treated patients. This simplification strategy reduced pill burden and preserved viral suppression in treatment-experienced patients with no major mutations to rilpivirine at historical genotyping.

Sign in / Sign up

Export Citation Format

Share Document